Telomerase-dependent oncolytic adenovirus for cancer treatment (Q45863661)

17 December 2017

title

Telomerase-dependent oncolytic adenovirus for cancer treatment (English)

1 reference

17 December 2017

1 reference

1 reference

Huang TG

1

1 reference

17 December 2017

Savontaus MJ

2

1 reference

17 December 2017

Shinozaki K

3

1 reference

17 December 2017

Sauter BV

4

1 reference

17 December 2017

Woo SL

5

1 reference

17 December 2017

publication date

1 August 2003

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

10

1 reference

17 December 2017

issue

15

1 reference

17 December 2017

page(s)

1241-1247

1 reference

17 December 2017

Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Replicative adenoviruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

21 January 2018

Telomerase and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Telomerase RNA expression during progression of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Inhibition of telomerase limits the growth of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

inferred from DOI database lookup

7 January 2021

based on heuristic

Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301987

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3301987

1 reference

17 December 2017

Dimensions Publication ID

1013682988

0 references

1 reference

17 December 2017